Summary & Overview
HCPCS C9169: Intravesical Injection of Nogapendekin Alfa Inbakicept-pmln, 1 mcg
HCPCS Level II code C9169 represents an intravesical injection of nogapendekin alfa inbakicept-pmln, dosed per microgram, intended for direct bladder administration. This code identifies a specific biologic product and route of administration that can affect coding, billing, and coverage determinations for urology and oncology procedural care. Nationally, distinct HCPCS codes for proprietary biologics inform payer coverage policies, prior authorization workflows, and reimbursement reporting.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical and service context, typical sites of service, and which payers are evaluated. The publication outlines expected benchmarks and policy considerations relevant to hospital outpatient departments, ambulatory infusion centers, and urology clinics that provide intravesical biologic therapies.
The report also summarizes common billing modifiers encountered with device and biologic administrations, notes when data are not available from the input, and points to clinical context that affects claim adjudication (product-specific coding, route of administration, and unit-based dosing). The content is intended to support billing staff, revenue cycle managers, and policy analysts in understanding how HCPCS Level II code C9169 is used in claims and coverage workflows.
Billing Code Overview
HCPCS Level II code C9169 describes an intravesical injection formulation: injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram. The service involves administering the specified biologic agent directly into the bladder (intravesical route) for localized treatment.
Service Type: Intravesical injection of a biologic agent
Typical Site of Service: Ambulatory infusion or procedure suite, hospital outpatient department, or urology clinic where intravesical therapies are performed
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with nonmuscle invasive bladder cancer (NMIBC) or high-risk superficial bladder carcinoma undergoing intravesical therapy. The patient presents to an outpatient urology infusion or procedure suite for intravesical administration of C9169 (nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram) as part of bladder-directed biologic therapy. Pre-procedure workflow includes verification of indication, review of prior cystoscopy and pathology, informed consent, medication preparation by pharmacy under aseptic technique, and placement of a urinary catheter or use of an existing catheter for bladder instillation. The bladder is drained, the prepared dose is instilled intravesically, and the patient is instructed to retain the medication for the prescribed dwell time (commonly 1–2 hours) unless contraindicated. Post-instillation monitoring includes observation for urinary retention, dysuria, hematuria, allergic reaction, or systemic adverse effects. Documentation includes medication lot number, dose in micrograms, route intravesical, time instilled and expired, catheter details, patient tolerance, and any immediate complications. Typical sites of service are outpatient urology clinics, ambulatory infusion centers, hospital outpatient departments, or procedure suites equipped for intravesical administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |